845290-58-6 Usage
Uses
Used in Pharmaceutical Industry:
CHEMBRDG-BB 4002269 is used as a potential therapeutic agent for various diseases and conditions due to its pharmacological properties. Its anti-inflammatory and antioxidant effects make it a candidate for the treatment of conditions such as cancer, diabetes, and cardiovascular diseases.
Used in Drug Discovery:
In the field of drug discovery, CHEMBRDG-BB 4002269 is utilized as a promising candidate for further research and development. Its potential pharmacological properties and wide range of applications in treating various diseases make it a valuable asset for the development of new medications and therapies.
Used in Medicinal Chemistry Research:
CHEMBRDG-BB 4002269 is employed as a subject of study in medicinal chemistry research to explore its potential applications and mechanisms of action. This research aims to better understand the compound's properties and how they can be harnessed for the development of new drugs and therapies to treat a variety of diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 845290-58-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,2,9 and 0 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 845290-58:
(8*8)+(7*4)+(6*5)+(5*2)+(4*9)+(3*0)+(2*5)+(1*8)=186
186 % 10 = 6
So 845290-58-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H20N2/c1-12-7-3-5-10(9-12)4-2-6-11-8-10/h11H,2-9H2,1H3
845290-58-6Relevant academic research and scientific papers
Synthesis and differential functionalisation of pyrrolidine and piperidine based spirodiamine scaffolds
Weinberg, Kamil,Stoit, Axel,Kruse, Chris G.,Haddow, Mairi F.,Gallagher, Timothy
, p. 4694 - 4707 (2013/07/04)
The synthesis and differential substitution/protection of a series of spirodiamine scaffolds are described. Methods for selective access to the two mono-N-methyl isomers based on 2,7-diazaspiro[4.5]decane are also described. Key precursors associated with this chemistry are prone to rearrangement and methods for circumventing this issue are reported. While direct mono-carbamoylation (Boc) was not efficient, selective deprotection of doubly Boc-protected derivatives derived from symmetrical diamines provided mono-Boc variants. N-Arylation, exemplified by a series of monosubstituted spirodiamines incorporating the 2-chloro-5-pyridyl moiety, which is a privileged nicotinic agonist substructure, has also been carried out to provide monoarylated secondary and tertiary spirodiamines variants.
